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the total direct and indirect cost increase was approximately
$120 per person per month.
SMOKING—Cost Studies
PSM1
A LONG TERM COST–EFFECTIVENESS ANALYSIS MODEL FOR
SMOKING CESSATION IN MEXICO
Mould-Quevedo J, Saenz-Montanez J, Davila-Loaiza G
Pﬁzer Mexico, Mexico City, Mexico
OBJECTIVES: Smoking is associated with several acute and
chronic diseases in adult population that generate high medical
costs in the Mexican Health System. The purpose of the study
was to model the long term economic and health consequences
of two smoking cessation interventions (SCI) in Mexican
smokers attempting to quit from the health care payer’s per-
spective. METHODS: A cost–effectiveness assessment was devel-
oped using a Markov modeling approach adapted to the
Mexican smoker population. The model simulates costs and
effectiveness outcomes in a twenty-year period (1-year cycle) and
includes four potential comorbidities: chronic obstructive pul-
monary disease, lung cancer, coronary heart disease and stroke.
Comparators were: varenicline vs. nicotine patches, both in a
twelve-week treatment. Transition probabilities were obtained
according to Mexican epidemiologic data. Quit successful rates,
smoking relapses rates and relative risk of smoking associated to
the mentioned comorbidities were obtained from clinical trials
published in the literature. Effectiveness measure was the number
of life-years gained (LYG). Resource use and costs data was
obtained from representative published Mexican institutional
databases (only direct medical costs were included). Costs and
effectiveness measures were discounted 3% annually. Proba-
bilistic sensitivity analysis was performed and acceptability
curves were constructed. RESULTS: Varenicline, in a 20-year
period analysis, showed that could generate 132,304 more quit-
ters (4.9%); 4905 less subjects with comorbidities (1.5%); 3333
deaths avoided; and 22,598 LYG in comparison to the treatment
with nicotine patches. Also, varenicline was in the long term a
cost-saving strategy (expected cost reduction of US$10.6 mil-
lions—CI 95% US$9.8–US$11.7 millions). Results were robust
to Monte Carlo second order sensitivity analysis and accept-
ability curves showed the same results with a mean of 70% of
certainty. CONCLUSION: Despite its higher cost in the Mexican
market, varenicline was the SCI most cost–effective in the long
term for the management of patients attempting to quit.
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OBJECTIVES: To calculate incremental cost-utility ratios for
varenicline as compared to bupropion in smoking cessation in
Sweden for a follow-up period of 20 and 50 years, respectively.
METHODS: The Beneﬁts of Smoking Cessation on Outcomes
(BENESCO) simulation model was employed in order to calcu-
late costs and beneﬁts accruing from smoking cessation. The
BENESCO model simulates morbidity and mortality over time
for a Swedish population of smokers. Four diseases were con-
sidered: chronic obstructive pulmonary disease, coronary heart
disease, stroke, and lung cancer. According to available epi-
demiological evidence, these diseases cover most of the health
problems associated with smoking. The advantage of smoking
cessation, simulated by the BENESCO model, is the decreased
incidence of the diseases considered. The beneﬁts of smoking ces-
sation were simulated for a male and female cohort, respectively.
In addition, the BENESCO model was extended in order to
include the indirect effects of smoking cessation on production
and consumption in the economy. All calculations were per-
formed in 2003 Swedish prices, assuming that 25% of the
smokers in each age-group make one attempt to quit smoking at
the outset of the simulation. RESULTS: Including indirect effects
on production, the incremental costs per QALY gained were
€2062 for men and €1196 for women over 20 years of follow-
up and €14,783 for men and €14,252 for women over 50 years
of follow-up, compared with bupropion. Including only direct
effects on health care costs, smoking cessation using varenicline
was cost-saving compared to bupropion treatment. Sensitivity
analysis indicated that the results are robust. Variation of treat-
ment efﬁciency and intervention cost, respectively, had a larger
effect on cost per QALY gained than other variables. CON-
CLUSION: Based on this model, the estimated costs per QALY
gained demonstrated that smoking cessation intervention using
varenicline was among the most cost effective, life-saving
medical treatments.
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OBJECTIVES: To estimate the incidence and prevalence of the
most burdensome smoking related morbidities in the US popu-
lation as part of the Beneﬁts of Smoking Cessation on Outcomes
(BENESCO) model. METHODS: We have developed a micro-
simulation Markov model to estimate the outcomes and costs of
a hypothetical cohort of US current smokers, a proportion of
whom (25%) will make a single attempt to quit smoking in the
ﬁrst year of a lifetime model. The BENESCO model estimates
the incidence and prevalence of smoking related diseases by using
the relative risks for mortality of the diseases as a proxy. The
hazard ratios from the Cancer Prevention Study II (Thun 2000)
were used as the basis for the required transformations. The inci-
dence and prevalence of the following smoking related diseases
were included in the model: lung cancer, chronic obstructive pul-
monary disease (COPD), coronary heart disease (CHD), stroke
and asthma exacerbations (attributed to smoking). Although the
model includes smokers aged 18 years and older, no excess events
were assumed to occur before the age of 35. RESULTS: Of 
the morbidities modelled, COPD was found as the most pre-
valent [peak estimates of individuals affected at model entry
point] disease among smokers [2.89 million], followed by CHD
[1.8 million], stroke [449,991], asthma exacerbations [395,829]
and lung cancer [68,348]. Incidence rates at model entry fol-
lowed a similar pattern to prevalence. The morbidities, which
were modelled, were more prevalent overall in female smokers
than their male counterparts. CONCLUSION: The estimates of
the incidence and prevalence of smoking related diseases in the
US population rely on methodology, which has been used else-
where in published, validated models (Orme 2001, Hoogen-
doorn 2003) and use underlying hazard ratios from a large,
independent US public health study. As such it could be expected
that the external validity of the estimates in the BENESCO model
is acceptable.
